CN111728030B - Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof - Google Patents
Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof Download PDFInfo
- Publication number
- CN111728030B CN111728030B CN202010518902.XA CN202010518902A CN111728030B CN 111728030 B CN111728030 B CN 111728030B CN 202010518902 A CN202010518902 A CN 202010518902A CN 111728030 B CN111728030 B CN 111728030B
- Authority
- CN
- China
- Prior art keywords
- immunity
- sucrose
- lactobacillus helveticus
- cooling
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013618 yogurt Nutrition 0.000 title claims abstract description 104
- 230000036039 immunity Effects 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 75
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 73
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 73
- 239000000843 powder Substances 0.000 claims abstract description 42
- 239000008267 milk Substances 0.000 claims abstract description 33
- 235000013336 milk Nutrition 0.000 claims abstract description 32
- 210000004080 milk Anatomy 0.000 claims abstract description 32
- 230000002708 enhancing effect Effects 0.000 claims abstract description 18
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 238000001816 cooling Methods 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 40
- 241000894006 Bacteria Species 0.000 claims description 33
- 238000011049 filling Methods 0.000 claims description 33
- 239000003292 glue Substances 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 19
- 229940032147 starch Drugs 0.000 claims description 19
- 238000010008 shearing Methods 0.000 claims description 18
- 239000003381 stabilizer Substances 0.000 claims description 18
- 238000007789 sealing Methods 0.000 claims description 17
- 235000003599 food sweetener Nutrition 0.000 claims description 16
- 150000005846 sugar alcohols Chemical class 0.000 claims description 16
- 239000003765 sweetening agent Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- 235000008939 whole milk Nutrition 0.000 claims description 14
- 238000000265 homogenisation Methods 0.000 claims description 13
- 229920002148 Gellan gum Polymers 0.000 claims description 12
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 claims description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 235000010492 gellan gum Nutrition 0.000 claims description 12
- 239000000216 gellan gum Substances 0.000 claims description 12
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 claims description 12
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 claims description 12
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 claims description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 239000000811 xylitol Substances 0.000 claims description 12
- 235000010447 xylitol Nutrition 0.000 claims description 12
- 229960002675 xylitol Drugs 0.000 claims description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 235000018735 Sambucus canadensis Nutrition 0.000 claims description 10
- 235000007123 blue elder Nutrition 0.000 claims description 10
- 235000007124 elderberry Nutrition 0.000 claims description 10
- 235000008995 european elder Nutrition 0.000 claims description 10
- 240000008397 Ganoderma lucidum Species 0.000 claims description 8
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 7
- 241000241413 Propolis Species 0.000 claims description 7
- 239000008272 agar Substances 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 229940069949 propolis Drugs 0.000 claims description 7
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 6
- 241000026010 Dendrobium candidum Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 6
- 229960004998 acesulfame potassium Drugs 0.000 claims description 6
- 239000000619 acesulfame-K Substances 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- 235000013804 distarch phosphate Nutrition 0.000 claims description 6
- 239000001245 distarch phosphate Substances 0.000 claims description 6
- 235000010449 maltitol Nutrition 0.000 claims description 6
- 239000000845 maltitol Substances 0.000 claims description 6
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 6
- 229940035436 maltitol Drugs 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 3
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 3
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 240000003394 Malpighia glabra Species 0.000 claims description 3
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 claims description 2
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000107 Acetylated distarch adipate Polymers 0.000 claims description 2
- 239000004377 Alitame Substances 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 235000019409 alitame Nutrition 0.000 claims description 2
- 108010009985 alitame Proteins 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000008236 heating water Substances 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229930189775 mogroside Natural products 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 229940080313 sodium starch Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- -1 /or Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 244000151637 Sambucus canadensis Species 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 abstract description 5
- 235000020247 cow milk Nutrition 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 235000020122 reconstituted milk Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 210000000952 spleen Anatomy 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 229910021642 ultra pure water Inorganic materials 0.000 description 21
- 239000012498 ultrapure water Substances 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 210000000822 natural killer cell Anatomy 0.000 description 18
- 239000006041 probiotic Substances 0.000 description 17
- 235000018291 probiotics Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000036737 immune function Effects 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 239000000110 cooling liquid Substances 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 241000208829 Sambucus Species 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000008223 sterile water Substances 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000222336 Ganoderma Species 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000009928 pasteurization Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010013198 Daptomycin Proteins 0.000 description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 4
- 229960005484 daptomycin Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 229960002182 imipenem Drugs 0.000 description 4
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960003907 linezolid Drugs 0.000 description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 4
- 229960002260 meropenem Drugs 0.000 description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 description 3
- 241000607762 Shigella flexneri Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000013995 raspberry juice Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VOXXWSYKYCBWHO-QMMMGPOBSA-N (S)-3-phenyllactic acid Chemical compound OC(=O)[C@@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-QMMMGPOBSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 229960003734 levamisole hydrochloride Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2220/00—Biochemical treatment
- A23C2220/20—Treatment with microorganisms
- A23C2220/204—Use of bacteria which are encapsulated, entrapped or immobilised; Fermentation with these bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of foods, and discloses a normal-temperature sucrose-free yogurt with a long shelf life for improving immunity and a preparation method thereof. The normal-temperature long-shelf-life sucrose-free yoghurt for improving immunity comprises raw milk or milk powder and an immunity-improving functional component; the immunity enhancing functional ingredient at least comprises lactobacillus helveticus and/or mutants thereof. The yoghurt is prepared by fermenting cow milk or reconstituted milk through lactobacillus helveticus, and is compounded with various natural functional components for improving immunity, so that the immunity of a human body can be improved after long-term eating; in addition, the lactobacillus helveticus WH2580 still has the immunity enhancing effect in the inactivated state, so that the yoghourt can be normally stored under the normal temperature condition, does not need refrigeration, and has long shelf life.
Description
Technical Field
The invention relates to the technical field of foods, in particular to a normal-temperature sucrose-free yoghurt with long shelf life for improving immunity and a preparation method thereof.
Background
The autumn and winter seasons are the time period of the disease, and various epidemic diseases such as influenza begin to be abused, and children and old people with lower immunity are more ill disaster areas. The so-called "immunity" is the best doctor. The measures such as wearing a mask, washing hands and the like can only prevent external viruses from invading, and the immunity of the patient is the only force the patient can depend on once the patient is infected without special medicine.
Cow milk is nutritious and contains various unique components capable of regulating immune function, such as immunoglobulin, lactoferrin and various amino acids. The lysozyme and lactoperoxidase contained in the dairy product can play an anti-infective role in the intestines, activate an immune system, strengthen the activity of immune cells or improve the resistance of organisms to pathogenic bacteria, and protect the immune function of the bodies.
At present, a great deal of literature reports that probiotics can improve human immunity, such as lactobacillus reuteri can colonize in intestinal tracts, improve intestinal flora distribution, antagonize harmful bacteria, grow and improve host immunity. Meanwhile, lactobacillus reuteri can produce 'reuterin', and can widely inhibit the growth of gram-negative bacteria, gram-positive bacteria, yeast, fungi, protozoa and the like; lactobacillus rhamnosus LGG can increase secretion of intestinal mucosa IgA, and tissue pathogenic bacteria infect epithelial cells to enhance immunity; lactobacillus plantarum Lp9 and Lp91 can secrete anti-inflammatory cytokines in LPS-induced HT-29 cells, regulating immune function. A German study also shows that D-phenyllactic acid produced by lactobacillus fermentation can activate G protein receptor HCA3 of human immune system, cause chemotaxis of neutrophils and promote immunity. Brazil researchers found that acetate produced by lactic acid bacteria fermentation stimulated human GPR43-1 type interferon response against respiratory syncytial virus.
Propolis, ganoderma extract, wall-broken Ganoderma spore powder, beta-glucan, herba Dendrobii extract, herba Sambuci Williamsii, and acerola cherry etc. are generally considered to be rich in substances which are helpful for immunity, such as flavone, polyphenol, ganoderic acid, fungus polysaccharide, mucopolysaccharide, anthocyanin, vitamin C, etc.
When the cow milk capable of improving the human immunity is fermented by probiotics capable of improving the human immunity, and is supplemented with the functional components capable of improving the human immunity, the three-strength combination and the synergy are combined, so that a good immunity enhancing effect can be achieved.
At present, yogurt capable of enhancing immunity is declared on the market as shown in fig. 2, and probiotics used by the yogurt only have the function of adjusting immunity in a living state, so that the yogurt can be stored in a refrigerating mode, the shelf life is short (generally 15-21 days), and sugar substances such as white granulated sugar and the like are required to be added as carbon sources to maintain the activity of the strain. The refrigerated storage represents that the product has harsh requirements on storage, logistics and sales environments, and the intermediate cost is high; the product is easy to expire due to the short shelf life, so that waste is caused; white granulated sugar is one of the leading causes of obesity in this century, and is now widely subject to consumer and industry problems. But the normal temperature long shelf life (3-6 months) sucrose-free yoghurt capable of improving immunity is still a market blank at present.
Disclosure of Invention
In order to solve the technical problems, the invention provides the normal-temperature sucrose-free yoghurt with long shelf life for improving the immunity and the preparation method thereof. The yogurt can effectively improve immunity, can be stored normally at normal temperature, does not need refrigeration, and has long shelf life.
The specific technical scheme of the invention is as follows:
a sucrose-free yogurt with improved immunity and long shelf life at normal temperature comprises raw milk or milk powder and effective components for improving immunity; the immunity enhancing functional ingredient at least comprises lactobacillus helveticus and/or mutants thereof;
the lactobacillus helveticus is named WHH2580, and the microorganism deposit number is: CGMCC No.18730, and the microorganism classification is named as Lactobacillus helveticus Lactobacillus helveticus; the lactobacillus helveticus has a 16s rRNA gene sequence shown as SEQ ID NO. 1; the mutant is obtained by carrying out mutagenesis, domestication, gene recombination or natural mutation on the lactobacillus helveticus.
The lactobacillus helveticus WHH2580 used in the invention is a probiotic bacterial strain screened from yoghourt collected from Xinjiang Nalatin red mountain furrows, and proved by animal experiments, the probiotic bacterial strain has excellent adhesion performance, can smoothly reach intestinal tracts, can adhere to intestinal epithelial cells, and plays a probiotic effect; the strain can improve in vitro spleen lymphocyte proliferation and secretion of interleukin IL-12 by spleen lymphocytes, and promote secretion of interleukin IL-8 by human colon cancer epithelial cells HT-29; in addition, in an animal model with low immunity, the strain can also remarkably improve the organ index of mice, promote the proliferation of spleen lymphocytes and improve the activity of NK cells. Therefore, the lactobacillus helveticus WH2580 has good immunity enhancing effect. More importantly, the strain still has better immunity enhancing function after inactivation. In addition, in the animal experiment process, the bad states such as death, listlessness, inappetence and the like of the experimental animal are not found, which indicates that the strain has higher safety.
Specifically, the lactobacillus helveticus WHH2580 has the following advantages:
(1) Both living and non-living bodies have excellent adhesion characteristics: the method has the advantages that the method shows excellent adhesion capability in a human colon cancer epithelial cell HT-29 cell model test, the number of single-cell adhesion living bacteria reaches 15.69+/-5.94, the number of single-cell adhesion non-living bacteria reaches 11.59 +/-4.02, and the adhesion capability is obviously better than that of positive control strains lactobacillus rhamnosus LGG and Tian Zhu LcS. The strain can adhere to intestinal epithelial cells to exert physiological effects. Although adhesion is not a prerequisite for the bacterial strain to possess probiotic properties, the interaction of probiotics with the intestinal mucosa is considered critical for a number of reasons. Binding to the intestinal mucosa may extend the time that the probiotic bacterial strain is present in the intestine. This interaction with the mucosa brings the probiotics into close contact with the intestinal immune system, giving it a better opportunity to modulate the immune response. It can also fight intestinal pathogens by limiting its ability to reside in the intestine.
(2) Has good acid resistance and bile salt resistance: in the environment with the pH value of 3.0, the survival of the bacteria is not affected significantly by incubation for 2 hours, and the number of the living bacteria is reduced by 0.9 order of magnitude after 3 hours; pepsin has no obvious effect on the viability of the strain in 2 hours, and the number of living strains in 3 hours is reduced by 0.7 order of magnitude; 3h reduction by 3.6 orders of magnitude in 0.5% bile salt system. The acid resistance and the bile salt resistance are good, so that the feed can better pass through the stomach and the duodenum and smoothly reach the intestinal tract, thereby better playing a probiotic role; the good acid resistance enables the yoghurt to be suitable for a wider pH range in the fermentation process of preparing the yoghurt.
(3) In an in vitro cell test, the proliferation of in vitro spleen lymphocytes can be promoted, the multiplication factor of the inducer without the inducer is 1.912+/-0.087, and the multiplication factor of the inducer is 1.533+/-0.109. Can promote the secretion of interleukin IL-12 by spleen lymphocytes in vitro; the IL-12/IL-10 ratio was not significantly different from the Lactobacillus rhamnosus LGG. In an in vitro cell test, the human colon cancer epithelial cell HT-29 can be promoted to secrete interleukin IL-8; the secreted IL-8 was stimulated significantly higher than the commercial strain LGG.
(4) Has good inhibition effect on staphylococcus aureus, salmonella paratyphi B, escherichia coli, shigella flexneri and micrococcus luteus, so that pathogenic bacteria in intestinal tracts can be well inhibited in the intestinal tracts, intestinal flora is regulated, and the probiotic effect is exerted.
(5) Both living and non-living subjects have an enhanced immune function: the concentration of live strain is 2×10 8 CFU/d, concentration of fire-extinguishing strain taken 2X 10 8 CFU/d can significantly improve the organ index of mice, promote the proliferation of spleen lymphocytes and improve the activity of NK cells. This allows the probiotics in the yoghurt of the invention to exist in a non-living form, so that the yoghurt can have a longer shelf life at normal temperature without refrigeration.
Preferably, the yoghurt further comprises sugar alcohols, starch, stabilizers, sweeteners.
Preferably, the yoghurt comprises, by mass, 40% -85% of raw milk or 5-15% of milk powder, 0.001-0.020% of lactobacillus helveticus and/or a mutant thereof, 0.01-10.00% of an immunity-improving functional ingredient except lactobacillus helveticus and/or a mutant thereof, 0.5-5.0% of sugar alcohol, 0.1-5.0% of starch, 0.01-1.00% of a stabilizer, 0.001-0.050% of a sweetener, and the balance of water; the sum of all the raw materials is 100%.
The mass percentage refers to the percentage of the total mass of the yoghurt.
Preferably, the milk powder is one or more of full cream milk powder, defatted milk powder, whey protein powder and full milk protein powder.
Preferably, the immunity enhancing functional ingredient further comprises one or more of propolis, ganoderma lucidum extract, wall-broken ganoderma lucidum spore powder, beta-glucan, dendrobium candidum extract, elderberry and acerola cherry.
Preferably, the sugar alcohol is one or more of xylitol, maltitol, erythritol, sorbitol, isomalt and lactitol.
Preferably, the starch is one or more of physical starch, acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate and acetylated distarch adipate.
Preferably, the stabilizer is one or more of sodium carboxymethyl cellulose, pectin, soybean polysaccharide, agar, sodium caseinate, propylene glycol alginate, gelatin, gellan gum, guar gum and xanthan gum.
Preferably, the sweetener is one or more of acesulfame potassium, aspartame, sucralose, stevioside, mogroside, isomaltulose, alitame and neotame.
The method for preparing the normal-temperature long-shelf-life sucrose-free yoghurt for improving the immunity comprises the following steps of:
scheme a:
(1) Homogenizing and sterilizing: preheating raw milk, homogenizing, sterilizing, and cooling to obtain sterilizing and cooling feed liquid;
(2) Inoculating and fermenting: adding lactobacillus helveticus and/or mutants thereof into the sterilization cooling feed liquid obtained in the step (1), stirring and mixing uniformly, and standing and fermenting at constant temperature to obtain a yoghurt base material;
(3) Preparing glue solution: preheating water, adding stabilizer in the amount of formula into water, shearing or stirring, and cooling to obtain glue solution;
(4) And (3) secondary batching: cooling the yoghurt base material obtained in the step (2), and then stirring and demulsifying; adding the glue solution obtained in the step (3), adding the immunity-improving functional components except lactobacillus helveticus and/or the mutant thereof, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and fixing the volume by water to obtain feed liquid;
(5) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step (4);
(6) Filling and sterilizing: filling, sealing, pasteurizing and cooling the homogenized feed liquid in the step (5) to obtain the normal-temperature long-shelf-life sucrose-free yoghourt capable of improving the immunity; or sterilizing the homogenized feed liquid in the step (5) by UHT, hot filling or sterile cold filling, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yoghurt with improved immunity;
scheme B:
1) Preparing milk: heating water, adding milk powder with the formula amount into the water, stirring or shearing, standing and hydrating to obtain milk;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1), homogenizing, sterilizing and cooling to obtain sterilizing and cooling feed liquid;
3) Inoculating and fermenting: adding lactobacillus helveticus and/or mutants thereof into the sterilization cooling feed liquid obtained in the step 2), stirring and mixing uniformly, and standing and fermenting at constant temperature to obtain a yoghurt base material;
4) Preparing glue solution: preheating water, adding stabilizer in the amount of formula into water, shearing or stirring, and cooling to obtain glue solution;
5) And (3) secondary batching: cooling the yoghurt base obtained in the step 3), and then stirring to demulsify. Adding the glue solution obtained in the step 4), adding the immunity improving functional components except lactobacillus helveticus and/or the mutant thereof, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and fixing the volume by water to obtain feed liquid;
6) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step 5);
7) Filling and sterilizing: filling, sealing, pasteurizing and cooling the homogenized feed liquid in the step 6) to obtain the normal-temperature sucrose-free yogurt with long shelf life and improved immunity; or sterilizing the homogenized feed liquid in the step 6) by UHT, hot filling or sterile cold filling, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yogurt with improved immunity.
The invention prepares the yoghourt through pretreatment, homogenization, sterilization, fermentation, re-sterilization and filling of raw milk or milk powder and various raw and auxiliary materials, can be normally stored under normal temperature conditions, does not need refrigeration, and has a shelf life of 150-180 days; meanwhile, the functional components are kept to the maximum extent and are not damaged in the processing process, so that the functionality of the product is ensured.
Preferably, in step 1), the water has a mass of 200-400g.
Preferably, in step 1), the water is heated to a temperature of 45-60 ℃.
Preferably, in step 1), the stirring or shearing time is 15-30min.
Preferably, in step 1), the standing hydration time is 20-40min.
Preferably, in step (1) or step 2), the preheating is carried out to a temperature of 60-65 ℃.
Preferably, in step (1) or step 2), the homogenization pressure is 0-8/5-30MPa.
Preferably, in the step (1) or the step 2), the sterilization temperature is 90-97 ℃ and the time is 3-10min.
Preferably, in step (1) or step 2), the temperature is cooled to 35-45 ℃.
Preferably, in the step (2) or the step 3), the fermentation temperature is 35-45 ℃ and the fermentation time is 4-16h.
Preferably, in the step (2) or the step 3), the number of viable bacteria in the fermentation process is not less than 1×10 8 cfu/mL。
Preferably, in step (3) or step 4), the water has a mass of 200-400g.
Preferably, in step (3) or step 4), the water is preheated to a temperature of 50-60 ℃.
Preferably, in step (3) or step 4), the shearing or stirring time is 20 to 40 minutes.
Preferably, in step (3) or step 4), the temperature is cooled to 30 ℃ or lower.
Preferably, in step (4) or step 5), the temperature is cooled to 15 ℃ or lower.
Preferably, in step (4) or step 5), the volume is fixed to 1000mL with water.
Preferably, in step (5) or step 6), the homogenization pressure is 0-8/5-30MPa.
Compared with the prior art, the invention has the following advantages:
(1) The yoghurt is prepared by fermenting cow milk or reconstituted milk through lactobacillus helveticus WHH2580 and/or mutants thereof, and can be compounded with various natural functional components for improving the immunity, so that the immunity of a human body can be improved after long-term eating;
(2) The lactobacillus helveticus WHH-2580 used in the formula of the yoghurt disclosed by the invention is a probiotic with the function of improving immunity, and is characterized by still having the function of enhancing immunity in an inactivated state, so that the yoghurt disclosed by the invention can be subjected to pasteurization or UHT sterilization and has the characteristic of being preserved at normal temperature;
(3) The yoghurt is prepared by pretreatment, homogenization, sterilization, fermentation, re-sterilization and filling of raw milk or milk powder and various raw and auxiliary materials, can be normally stored under normal temperature conditions, does not need refrigeration, and has a shelf life of 150-180 days; meanwhile, the functional components are kept to the maximum extent and are not damaged in the processing process, so that the functionality of the product is ensured;
(4) The yogurt disclosed by the invention is free from adding sucrose, can be drunk by various people in daily life, and particularly has the advantages of high acceptability, high safety and no side effect, and has important efficacy value and social value for people with low autoimmune power and limited sugar intake (diabetes, obesity and the like) and people who are not loving cold food.
Drawings
FIG. 1 is a flow chart of a method for preparing sucrose-free yogurt with enhanced immunity and long shelf life at normal temperature;
FIG. 2 is a schematic flow chart of the preparation process of yoghurt capable of enhancing immunity in the prior art;
FIG. 3 is a schematic flow chart of the preparation of the normal temperature long shelf life sucrose-free yoghurt for improving immunity;
FIG. 4 is a graph of thymus index for each group of mice in example 4;
FIG. 5 is a graph showing the results of the experiment for transformation of spleen lymphocytes from mice of each group in example 4;
FIG. 6 is a graph of NK cell activity in each group of mice in example 4;
FIG. 7 shows the morphology of Lactobacillus helveticus WH2580 observed under a microscope;
FIG. 8 is a graph showing the effect of Lactobacillus helveticus WH2580 on adhesion of live, non-live, commercial strains LGG and Lcs to HT-29 cells;
FIG. 9 is a graph of the change in body weight of each group of BALB/c mice in the animal test of example 15;
FIG. 10 is a graph showing the organ ratio of each group of BALB/c mice in the animal test of example 15;
FIG. 11 is a graph showing the spleen lymphocyte transformation values for each group of BALB/c mice in the animal test of example 15;
FIG. 12 is a graph showing NK cell activity in each group of BALB/c mice in example 15.
Detailed Description
The invention is further described below with reference to examples.
General examples
The normal-temperature long-shelf-life sucrose-free yoghurt for improving immunity comprises, by mass, 40% -85% of raw milk or 5-15% of milk powder, 0.001-0.020% of lactobacillus helveticus and/or a mutant thereof, 0.01-10.00% of immunity-improving efficacy components except lactobacillus helveticus and/or a mutant thereof, 0.5-5.0% of sugar alcohol, 0.1-5.0% of starch, 0.01-1.00% of stabilizer, 0.001-0.050% of sweetener and the balance of water; the sum of all the raw materials is 100%.
The sucrose-free yoghurt with the normal temperature and long shelf life for improving the immunity is prepared by the following steps (the preparation flow is shown in figure 1, and the sketch is shown in figure 3):
scheme a:
(1) Homogenizing and sterilizing: preheating raw milk to 60-65deg.C, homogenizing under 0-8/5-30MPa; sterilizing at 90-97deg.C for 3-10min, and cooling to 35-45deg.C to obtain sterilizing and cooling liquid;
said sterilization is carried out under sterilization conditions conventional in the art, such as pasteurization;
(2) Inoculating and fermenting: adding Lactobacillus helveticus and/or its mutant into the sterilized cooling liquid obtained in step (1), stirring, mixing, standing at 35-45deg.C in constant temperature incubator for fermenting for 4-16 hr, and viable count not less than 1×10 8 cfu/mL to obtain a yoghurt base material;
(3) Preparing glue solution: weighing 200g-400g of ultrapure water, preheating to 50-60 ℃, adding stabilizer with the formula amount into the ultrapure water, shearing or stirring for 20-40min, and cooling to below 30 ℃ to obtain a glue solution;
(4) And (3) secondary batching: cooling the yoghurt base material obtained in the step (2) to below 15 ℃, and then stirring and demulsification; adding the glue solution obtained in the step (3), adding the immunity-improving functional components except lactobacillus helveticus and/or the mutant thereof, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and using ultrapure water to reach 1000mL to obtain feed liquid;
(5) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step (4), wherein the homogenizing pressure is 0-8/5-30MPa;
(6) Filling and sterilizing: filling the homogenized feed liquid in the step (5) into an HDPE packaging container, sealing, pasteurizing and cooling to obtain the normal-temperature long-shelf-life sucrose-free yoghourt capable of improving the immunity; or sterilizing the homogenized feed liquid in the step (5) by UHT, hot filling or sterile cold filling into a PET packaging container, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yogurt with improved immunity;
the pasteurization and UHT sterilization are the same as conventional sterilization conditions in the art.
Scheme B:
1) Preparing milk: weighing 200-400g of ultrapure water, heating to 45-60 ℃, adding the milk powder with the formula dosage into the ultrapure water, stirring or shearing for 15-30min, and standing for hydration for 20-40min;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1) to 60-65 ℃, and homogenizing under the homogenizing pressure of 0-8/5-30MPa; sterilizing at 90-97deg.C for 3-10min, and cooling to 35-45deg.C to obtain sterilizing and cooling liquid;
said sterilization is carried out under sterilization conditions conventional in the art, such as pasteurization;
3) Inoculating and fermenting: adding Lactobacillus helveticus and/or its mutant into the sterilized cooling liquid obtained in step 2), stirring, fermenting at 35-45deg.C for 4-16 hr in a constant temperature incubator, and keeping viable count at 1×10 or more 8 cfu/mL to obtain a yoghurt base material;
4) Preparing glue solution: weighing 200g-400g of ultrapure water, preheating to 50-60 ℃, adding stabilizer with the formula amount into the ultrapure water, shearing or stirring for 20-40min, and cooling to below 30 ℃ to obtain a glue solution;
5) And (3) secondary batching: cooling the yoghurt base material obtained in the step 3) to below 15 ℃, and then stirring and demulsification; adding the glue solution obtained in the step 4), adding the immunity improving functional components except lactobacillus helveticus and/or the mutant thereof, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and using ultrapure water to reach 1000mL to obtain feed liquid;
6) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step 5), wherein the homogenizing pressure is 0-8/5-30MPa;
7) Filling and sterilizing: filling the homogenized feed liquid in the step 6) into an HDPE packaging container, sealing, pasteurizing and cooling to obtain the normal-temperature sucrose-free yogurt with long shelf life and improved immunity; or sterilizing the homogenized feed liquid in the step 6) by UHT, hot filling or sterile cold filling into a PET packaging container, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yogurt for improving immunity;
the pasteurization and UHT sterilization are the same as conventional sterilization conditions in the art.
Example 1
The components of the embodiment consist of whole milk powder, xylitol, concentrated elderberry juice, hydroxypropyl distarch phosphate, sodium carboxymethyl cellulose, gellan gum, sucralose, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 100 g of whole milk powder, 20 g of xylitol, 0.1 g of sucralose, 5 g of concentrated elder raspberry juice, 5 g of hydroxypropyl distarch phosphate, 5 g of sodium carboxymethyl cellulose, 0.2 g of gellan gum, 0.02 g of Lactobacillus helveticus WHH-2580 and the balance of water.
The preparation steps of this example are as follows:
1) Preparing milk: weighing 300g of ultrapure water, preheating to 55 ℃, adding full-cream milk powder with the formula dosage into the ultrapure water, shearing for 15min at medium speed, and standing for hydration for 20min;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1) to 65 ℃, and homogenizing under the pressure of 5/20Mpa; sterilizing at 95-96 deg.c for 5min, and cooling to 42 + -1 deg.c to obtain sterilizing and cooling liquid;
3) Inoculating and fermenting: adding Lactobacillus helveticus WHH-2580 into the sterilized cooling liquid obtained in step 2), stirring, fermenting at 42deg.C for 6 hr in a constant temperature incubator, and sterilizing with viable count of 1×10 or more 8 cfu/mL to obtain a yoghurt base material;
4) Preparing glue solution: weighing 300g of ultrapure water, heating to 55 ℃, adding stabilizer with the formula dosage into the ultrapure water, shearing at medium speed for 20min, and cooling to below 30 ℃ to obtain a glue solution;
5) And (3) secondary batching: cooling the yoghurt base material obtained in the step 3) to below 15 ℃, and then stirring and demulsification; adding the glue solution obtained in the step 4), adding sugar alcohol, sweetener, starch and immunity improving functional components except lactobacillus helveticus and/or mutant thereof in the formula dosage, mixing and stirring, and using ultrapure water to reach 1000mL to obtain feed liquid;
6) And (3) secondary homogenization: homogenizing the yoghurt base material obtained in the step 5), wherein the homogenizing pressure is 0/5MPa;
7) Filling and sterilizing: filling the homogenized feed liquid in the step 6) into a HDPE packaging container, sealing, pasteurizing at 87 ℃ for 18min, and cooling to obtain the sucrose-free yogurt with normal temperature and long shelf life, wherein the immunity of the yogurt can be improved.
Example 2
The components of the embodiment consist of whole milk powder, xylitol, concentrated elderberry juice, hydroxypropyl distarch phosphate, sodium carboxymethyl cellulose, gellan gum, acesulfame potassium, aspartame, lucid ganoderma extract, dendrobium candidum extract, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 105 g of whole milk powder, 15 g of xylitol, 1 g of elderberry concentrated juice, 10 g of hydroxypropyl distarch phosphate, 6 g of sodium carboxymethyl cellulose, 0.25 g of gellan gum, 0.1 g of acesulfame potassium, 0.1 g of aspartame, 2 g of lucid ganoderma extract, 2 g of dendrobium candidum extract, 0.05 g of lactobacillus helveticus WHH-2580 and the balance of water.
The preparation method of this example is the same as that of example 1.
Example 3
The components of the embodiment comprise whole milk powder, maltitol, acetylated distarch phosphate, pectin, soybean polysaccharide, stevioside, propolis, broken ganoderma lucidum spore powder, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 105 g of milk powder, 40 g of maltitol, 5 g of acetylated distarch phosphate, 5 g of pectin, 2 g of soybean polysaccharide, 0.2 g of stevioside, 2 g of propolis, 2 g of wall-broken ganoderma lucidum spore powder, 0.07 g of lactobacillus helveticus WHH-2580 and the balance of water.
The preparation method of this example is the same as that of example 1.
Example 4
The components of the embodiment consist of whole milk powder, xylitol, concentrated elderberry juice, hydroxypropyl distarch phosphate, sodium carboxymethyl cellulose, gellan gum, acesulfame potassium, aspartame, lucid ganoderma extract, dendrobium candidum extract, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 105 g of whole milk powder, 15 g of xylitol, 1 g of elderberry concentrated juice, 10 g of hydroxypropyl distarch phosphate, 6 g of sodium carboxymethyl cellulose, 0.25 g of gellan gum, 0.1 g of acesulfame potassium, 0.1 g of aspartame, 2 g of lucid ganoderma extract, 2 g of dendrobium candidum extract, 0.05 g of lactobacillus helveticus WHH-2580 and the balance of water.
The preparation steps of this example are as follows:
1) Preparing milk: weighing 300g of ultrapure water, preheating to 50 ℃, adding full-cream milk powder with the formula dosage into the ultrapure water, shearing for 15min at medium speed, and standing for hydration for 20min;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1) to 60 ℃, and homogenizing under the homogenizing pressure of 5/20MPa; sterilizing at 95-96 deg.C for 5min, and cooling to 37+ -1deg.C to obtain sterilizing and cooling liquid;
3) Inoculating and fermenting: adding Lactobacillus helveticus WHH-2580 into the sterilized cooling liquid obtained in step 2), stirring, fermenting at 37deg.C in a constant temperature incubator for 16 hr, and sterilizing with viable count of 1×10 or more 8 cfu/mL to obtain a yoghurt base material;
4) Preparing glue solution: weighing 300g of ultrapure water, heating to 55 ℃, adding stabilizer with the formula dosage into the ultrapure water, shearing at medium speed for 20min, and cooling to below 30 ℃ to obtain a glue solution;
5) And (3) secondary batching: cooling the yoghurt base material obtained in the step 3) to below 15 ℃, and then stirring and demulsification; adding the cooled stabilizer, adding sugar alcohol, sweetener, starch and immunity enhancing functional components except lactobacillus helveticus and/or its mutant, mixing, stirring, and adding ultrapure water to 1000mL to obtain feed liquid;
6) And (3) secondary homogenization: homogenizing the yoghurt base material obtained in the step 5), wherein the homogenizing pressure is 0/5Mpa;
7) Filling and sterilizing: and (3) sterilizing the homogenized feed liquid in the step (6) by UHT at 121 ℃ for 15 seconds, filling the sterilized feed liquid into a PET packaging container, and sealing the packaging container to obtain the normal-temperature sucrose-free yogurt with long shelf life, wherein the immunity of the yogurt can be improved.
Example 5
The components of the embodiment comprise whole milk powder, maltitol, acetylated distarch phosphate, pectin, soybean polysaccharide, stevioside, propolis, broken ganoderma lucidum spore powder, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 105 g of milk powder, 40 g of maltitol, 5 g of acetylated distarch phosphate, 5 g of pectin, 2 g of soybean polysaccharide, 0.2 g of stevioside, 2 g of propolis, 2 g of wall-broken ganoderma lucidum spore powder, 0.07 g of lactobacillus helveticus WHH-2580 and the balance of water.
The preparation method of this example was the same as that of example 4.
Example 6
The components of the embodiment consist of whole milk powder, xylitol, concentrated elderberry juice, hydroxypropyl distarch phosphate, sodium carboxymethyl cellulose, gellan gum, sucralose, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 100 g of whole milk powder, 20 g of xylitol, 0.1 g of sucralose, 5 g of concentrated elder raspberry juice, 5 g of hydroxypropyl distarch phosphate, 5 g of sodium carboxymethyl cellulose, 0.2 g of gellan gum, 0.02 g of Lactobacillus helveticus WHH-2580 and the balance of water.
The preparation method of this example was the same as that of example 4.
Example 7
The components of the embodiment comprise raw milk, xylitol, concentrated elderberry juice, hydroxypropyl distarch phosphate, sodium carboxymethyl cellulose, gellan gum, sucralose, lactobacillus helveticus WHH-2580 and purified water, wherein the weight of each component is 1000 milliliters in total: 700 g of raw milk, 20 g of xylitol, 0.1 g of sucralose, 5 g of concentrated elderberry juice, 5 g of hydroxypropyl distarch phosphate, 5 g of sodium carboxymethyl cellulose, 0.2 g of gellan gum, 0.02 g of Lactobacillus helveticus WHH-2580 and the balance of water.
The preparation steps of this example are as follows:
1) And (3) milk collection: cooling the raw milk which is qualified by inspection to 4 ℃ and collecting the raw milk into a milk storage tank;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1) to 65 ℃, and homogenizing under the homogenizing pressure of 5/20MPa; sterilizing at 95-96 deg.c for 8min, and cooling to 40+ -1 deg.c to obtain sterilizing and cooling liquid;
3) Inoculating and fermenting: adding Lactobacillus helveticus WHH-2580 into the sterilized cooling liquid obtained in step 2), stirring, fermenting at 40deg.C for 8 hr, and sterilizing with viable count of 1×10 or more 8 cfu/mL to obtain a yoghurt base material;
4) Preparing glue solution: weighing 250g of ultrapure water, heating to 55 ℃, adding stabilizer with the formula dosage into the ultrapure water, shearing at medium speed for 20min, and cooling to below 30 ℃ to obtain a glue solution;
5) And (3) secondary batching: cooling the yoghurt base material obtained in the step 3) to below 15 ℃, and then stirring and demulsification; adding the cooled stabilizer, adding sugar alcohol, sweetener, starch and immunity enhancing functional components except lactobacillus helveticus and/or its mutant, mixing, stirring, and adding ultrapure water to 1000mL to obtain feed liquid;
6) And (3) secondary homogenization: homogenizing the yoghurt base material obtained in the step 5), wherein the homogenizing pressure is 0/5Mpa;
7) Filling and sterilizing: filling the homogenized feed liquid in the step 6) into a HDPE packaging container, sealing, pasteurizing at 87 ℃ for 18min, and cooling to obtain the sucrose-free yogurt with normal temperature and long shelf life, wherein the immunity of the yogurt can be improved.
Example 8: functional test of the yoghurt obtained by the invention
Mice are fed with the yoghurt obtained in the embodiment 1 of the invention, and after a period of time, cyclophosphamide is injected as an immunosuppressant to observe the effect of the product on improving the immunity of the mice. Before sterilization, the number of the lactobacillus helveticus WHH-2580 obtained by the invention can reach 1 multiplied by 10 8 cfu/mL。
Inbred BALB/C male mice (6-8 weeks old, 16-20 g) were randomized into 4 groups with a 5 day adaptation period of 44, using a randomized group design: blank (CK), model (M), model+yogurt 5-fold (Y5) and model+yogurt 10-fold (Y10) groups each 11. The 5-time yoghurt group and the 10-time yoghurt group respectively simulate normal people (60 kg body weight) to take 200g and 400g of the normal-temperature long-shelf-life sucrose-free yoghurt capable of improving the immunity.
The animal feeding keeps the ambient temperature at 21+/-2 ℃, the humidity at 30-70%, the illumination is alternated for 12 hours, the animals can drink water and take feed freely. The padding is changed every three days, and water and feed are added in time. The subjects were administered continuously for 33 days. The molding drug used was cyclophosphamide (50 mg/kg, intraperitoneal injection, two consecutive days), and mice were sacrificed 5 days after molding, and thymus/body weight ratio was measured, and spleen lymphocyte transformation (MTT method) experiment and NK cell activity measurement were performed.
Grouping condition:
group 1 blank (n=11): gastric lavage water;
group 2 model group (n=11): pouring stomach water and molding cyclophosphamide;
group 3 modeling + yogurt 5-fold group (n=11): filling stomach 5 times of yoghourt 0.2 ml/d, and molding cyclophosphamide;
group 4 modeling + yogurt 10-fold group (n=11): and (3) pouring 10 times of yoghourt of 0.2 ml/d into the stomach, and molding cyclophosphamide.
Thymus index: as shown in fig. 4, the thymus/body weight ratio was significantly lower in the model group than in the blank group (P < 0.05), and there was no significant difference between the other model groups compared to the model group.
Mouse spleen lymphocyte transformation experiment: as shown in FIG. 5, the modeling groups were significantly worse (P < 0.05) than the model groups, indicating that each experimental group promoted proliferation of spleen lymphocytes in immunocompromised mice.
NK cell Activity assay: as shown in fig. 6, the NK cell activity of the model group was significantly lower than that of the blank group (P < 0.05). NK cell activity was significantly higher for the 5-fold and 10-fold yogurts than for the model group (P < 0.05).
According to the judging method of the result in the function evaluation method of the health care product, under the condition that an immune function hypofunction model is established, the total number of blood leucocytes, the cell immune function (a mouse spleen lymphocyte transformation experiment, a delayed type allergy experiment), the humoral immune function (antibody generation cell detection, serum hemolysin measurement), the mononuclear-macrophage function (a mouse carbon clearance experiment, a mouse peritoneal macrophage phagocytosis fluorescent microsphere experiment), the NK cell activity and the test result in any two aspects are positive, and the tested sample is judged to have the effect of enhancing the immunity of the immunocompetent person. In the animal experiment and the mouse spleen lymphocyte transformation experiment, OD values of 5 times of yoghourt groups and 10 times of yoghourt groups are obviously higher than those of a model group, and the result is positive. In the NK cell activity index, the NK cell activity of the 5-time yoghurt group and the 10-time yoghurt group is obviously higher than that of the model group, and the result is positive. Therefore, the 5-time yoghurt and the 10-time yoghurt are judged to have the function of enhancing the immunity of the mice with low immunity.
Example 9
The strain provided by the invention is identified as belonging to lactobacillus helveticus (Lactobacillus helveticus), and is named WH2580, and the microorganism preservation number is: CGMCC No.18730.
The strain provided by the invention is obtained by screening from yoghurt collected by red mountain ditches in Sinkiang Nalatin.
The biological properties of lactobacillus helveticus 2580 according to the present invention are as follows:
morphological features: the growth state in MRS agar medium is: the growth form of the strain in MRS agar culture medium is light milky colony, semitransparent, round, rough in surface, irregular in edge and flat. Gram staining was typically positive and cells were observed under a microscope to be long rod-like, flagellum free, sporulation free, and motionless (shown in fig. 7).
Culturing characteristics: the optimal growth temperature is 37 ℃, and the plant is facultative anaerobic and grows in MRS culture medium.
Physiological characteristics: using the API 50CHL system, WHH2580 strain can utilize 6 carbon sources: d-glucose, D-fructose, D-mannose, N-acetylglucosamine, D-lactose and D-trehalose.
Biological identification: the 16s rRNA gene sequence was sequenced, and the obtained results were subjected to homology alignment analysis with NCBI GenBank database, and the results showed that the strain was Lactobacillus helveticus (Lactobacillus helveticus).
The gene sequence is shown in SEQ ID NO. 1:
CCTTCCCGAAGGTTAGGCCACCGGCTTTGGGCATTGCAGACTTCCATGGTGTGACGGGC GGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTTCTGATCCGCGATTACTAGCGATTCCAGCTTCGTGCAGTCGAGTTGCAGACTGCAGTCCGAACTGAGAACAGCTTTCAGA GATTCGCTTGCCTTCGCAGGCTCGCTTCTCGTTGTACTGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCCGGTTTATCACC GGCAGTCTCATTAGAGTGCCCAACTTAATGCTGGCAACTAATAACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGT CTTAGCGTCCCCGAAGGGAACTCCTAATCTCTTAGGATGGCACTAGATGTCAAGACCTG GTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTAATGCGT TAGCTGCAGCACTGAGAGGCGGAAACCTCCCAACACTTAGCACTCATCGTTTACGGCATGGACTACCAGGGTATCTAATCCTGTTCGCTACCCATGCTTTCGAGCCTCAGCGTCAGTTG CAGACCAGAGAGTCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTCCACCGCTACACATGGAGTTCCACTCTCCTCTTCTGCACTCAAGAAAAACAGTTTCCGATGCAGTTC CTCGGTTAAGCCGAGGGCTTTCACATCAGACTTATTCTTCCGCCTGCGCTCGCTTTACGCCCAATAAATCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTTA GCCGTGACTTTCTGGTTGATTACCGTCAAATAAAGGCCAGTTACTACCTCTATCCTTCTTCACCAACAACAGAGCTTTACGATCCGAAAACCTTCTTCACTCACGCGGCGTTGCTCCATC AGACTTGCGTCCATTGTGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATTGCCTTGGTA AGCCGTTACCTTACCAACTAGCTAATGCACCGCGGGGCCATCCCATAGCGACAGCTTACGCCGCCTTTTATAAGCTGATCATGCGATCTGCTTTCTTATCCGGTATTAGCACCTGTTTCCA AGTGGTATCCCAGACTATGGGGCAGGTTCCCCACGTGTTACTCACCCATCCGCCGCTCGCGTCCCCAGCGTCATTACCGAAGTAAATCTGCTGGTTCTGCTCGCTCGACTTGC
example 10: strain tolerance
Acid and bile salt resistance of lactobacillus helveticus WHH2580 strain:
acid resistance 1: the second-generation activated strain WH 2580 was centrifuged at 20 mL/tube and washed twice with PBS at pH 7.2. The bacterial sludge was placed in 20mL sterile PBS pH3.0, PBS+0.3% pepsin pH3.0 and PBS pH7.2, respectively, and each system was replicated in duplicate. And (3) placing the sample at 37 ℃ and sampling at 0h, 1h, 2h and 3h respectively, and counting viable bacteria.
The acid resistance test results show that: pH3.0 had no significant effect on the viability of the bacteria at 2h, 3h viable count was reduced by 0.9 orders of magnitude. Pepsin pH3.0 had no significant effect on the viability of the bacteria at 2h, with a 0.7 order of magnitude reduction in the number of viable bacteria at 3 h. The above results indicate that the bacterium has excellent acid resistance.
2 bile salt resistance: the second-generation activated strain WH 2580 was centrifuged at 20 mL/tube and washed twice with PBS at pH 7.2. Bacterial sludge was placed in 20mL of sterile PBS+0.1%Trypsin pH8.0, PBS+0.3% BS pH8.0, PBS+0.5% BS pH8.0 and PBS pH7.2, respectively, and each system was replicated in duplicate. And (3) placing the sample at 37 ℃ and sampling at 0h, 1h, 2h and 3h respectively, and counting viable bacteria.
The results of the bile salt tolerance experiment show that: 3h in 0.1% Trypsin system was reduced by 0.8 orders of magnitude, 3h in 0.3% BS system was reduced by 2.8 orders of magnitude, and 3h in 0.5% BS system was reduced by 3.6 orders of magnitude. The results show that the strain has good cholate resistance.
Example 11: bacterial strain adhesion
The probiotics colonize the intestinal epithelial cells of the host through adhesion, gradually form a biological film and generate various metabolites, thereby forming a natural protective barrier and generating various physiological effects for the host. Thus, adhesion and colonization of probiotics on host intestinal epithelial cells is a prerequisite for their probiotic action.
HT-29 cells are used as cell lines for the adhesion test, and the specific experimental method is as follows:
HT-29 cells were transferred to the third generation, centrifuged at 1000rpm for 5min after digestion with 0.25% pancreatin, and resuspended in 5mL DMEM medium containing 10% foetal calf serum (100U/mL penicillin, 100mg/mL streptomycin) until the cells were in single cell suspension. Appropriate amount of cells were counted by using a hemocytometer, and diluted to a cell suspension concentration of 1X 10 in DMEM medium (penicillin 100U/mL, streptomycin 100 mg/mL) containing 10% fetal bovine serum 6 1mL of cells/mL was inoculated into 12-well cell culture plate on which cell slide had been placed, and incubated at 37℃with 5% CO 2 Culturing for 2 days.
After WH 2580 strain (lactobacillus rhamnosus LGG and generation Tian Zhu LcS are positive control strains) is subjected to second-generation activation, 10mL of bacterial liquid is taken, 4200g is centrifugated for 10min at room temperature to collect bacterial cells, 10mL of DMEM complete medium containing 10% fetal bovine serum is used for culturing (without adding diabody) and resuspension is carried out, and the bacterial concentration is regulated to 2X 10 8 CFU/mL. 5mL of strain regulating solution is taken for inactivation for 5min at 95 ℃. 1mL of each of the strain-adjusting solution and the inactivated strain-adjusting solution was inoculated into a 12-well cell culture plate on which a cell slide had been placed, each3 in parallel with CO 2 Incubate for 2h at 37℃in incubator.
After the incubation was completed, the culture broth was slowly aspirated, washed 3 times with PBS and fixed with 100% methanol for 8min. Taking out the cell climbing tablet, standing for 20min, and sealing the tablet with neutral resin after gram staining. Observations were made under an optical microscope.
Adhesion test results are shown in the following table.
The effect of Lactobacillus helveticus WH2580 viable, non-viable, commercial strains LGG and Lcs on HT-29 cell adhesion is shown in FIG. 8.
The adhesion capacity of the lactobacillus helveticus WH2580 viable bacteria and non-viable bacteria is obviously higher than that of positive control strains lactobacillus rhamnosus LGG and field-substituting strain LcS. The adhesion rate of the non-living bacteria of the Lactobacillus helveticus WH2580 is slightly lower than that of the living bacteria, but the adhesion effect of the non-living bacteria is better than that of the living bacteria, the number of bacteria among HT-29 cells is less, and most of the non-living bacteria are tightly adhered on the cells.
Example 12: bacterial strain resistance
Sensitivity to antibiotics of lactobacillus helveticus WHH2580 strain:
the sensitivity of probiotics to antibiotics is an important indicator for the safety of the detection strains. To test the safety of the WHH2580 strain, the following 9 antibiotics were selected for testing, and the sensitivity of the WHH2580 strain to the 9 antibiotics was tested, and the specific experimental design is as follows.
The antibiotic formulation concentrations were 0.5ug/mL, 1ug/mL, 2ug/mL, 4ug/mL, 8ug/mL, 16ug/mL, 32ug/mL, 64ug/mL, 128ug/mL, 256ug/mL, the actual effect concentrations were 0.125ug/mL, 0.25ug/mL, 0.5ug/mL, 1ug/mL, 2ug/mL, 4ug/mL, 8ug/mL, 16ug/mL, 32ug/mL, 64ug/mL.
Adding 100 μl of culture medium into each well of sterile 96-well polystyrene plate, adding 50 μl of antibiotic diluent (ug/mL) into each well according to the concentration of 2-11 columns, adding 50 μl of bacterial suspension (final concentration of bacterial liquid is 105-106 CFU/mL) into each well of 1-11 columns, sealing, placing in a 37 ℃ incubator for 24-48h,OD625 was visually observed and measured. Wherein lactobacillus rhamnosus LGG and generation Tian Zhu LcS are positive control strains.
Name of the name | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
Penicillin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Ampicillin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Imipenem | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Meropenem | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Vancomycin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Daptomycin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Erythromycin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Clindamycin | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
Linezolid | Sterile solvents | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | Sterile water |
The results of the experiments are shown in the following Table, MIC values ug/mL.
Based on the criterion of sensitivity of the CLSI M4 strain to antibiotics, the following conclusion was reached. WH 2580 strain is resistant to Daptomycin and Clindamycin, neutral to Erythromycin, and sensitive to Penicillin, ampicillin, imipenem, meropenem, vancomycin and Linezolid. LGG strain is resistant to Imipenem, meropenem, vancomycin, daptomycin, clindamycin, neutral to Erythromycin, and sensitive to Penicillin, ampicillin and Linezolid. The LcS strain is resistant to Vancomycin and Daptomycin, neutral to Imipenem, meropenem and erythromycins, and sensitive to Penicillin, ampicillin, clindamycin and Linezolid.
Example 13: bacterial strain inhibiting pathogenic bacteria
Lactobacillus helveticus WH2580 strain bacteriostasis experiment:
sterilized 1.5% plain agar was previously dispensed onto sterile petri dishes. Placing oxford cup. Sterilizing 1% agar MRS culture medium or NB culture medium, inoculating at below 50deg.C for 10 6 -10 7 Five indicator bacteria (Escherichia coli, staphylococcus aureus, shigella flexneri, salmonella paratyphi B, micrococcus luteus) at CFU/mL concentration were mixed with shaking and poured onto the previously poured oxford agar medium. After the culture medium is cooled and solidified, the oxford cup is pulled out. 100uL of the corresponding bacterial solution (WH2580) and positive control (10 g/mL polymyxin B or 1% nisin) were added to different wells, and the wells were placed in a refrigerator at 4℃for 7h for diffusion. After incubation at 37℃for 16h, the size of the zone of inhibition was observed and recorded.
The experimental results are shown in the following table, and the numerical values in the table are cm of the size of the inhibition zone.
Experimental results show that WH 2580 strain has inhibition effect on 5 pathogenic bacteria, has no obvious difference on inhibition effect on salmonella paratyphi B, escherichia coli and shigella flexneri and 10g/mL polymyxin B, has no obvious difference on inhibition effect on staphylococcus aureus and 1% nisin, and is slightly lower than other control strains.
Example 14: the strain has immunity enhancing function
1. In vitro spleen lymphocyte proliferation:
killing mice, aseptically taking spleen, cutting spleen with ophthalmic scissors, grinding with sterile glass syringe core, and passing through 200 mesh metalAfter filtration through a screen, cells were harvested by centrifugation at 1000rpm at 4℃for 5min in sterile Hank's solution containing 10% fetal bovine serum. Adding 5 times of cell volume of cell lysate, lysing for 5min, adding 10% fetal bovine serum containing sterile Hank's solution, stopping lysing, centrifuging at 1000rpm at 4deg.C for 5min, and removing supernatant. Washing with RPMI-1640 medium containing 10% fetal bovine serum, 1000rpm, and centrifuging at 4deg.C for 5min. The pellet was resuspended in 5mL of RPMI-1640 medium containing 10% fetal bovine serum. Cell count, and cell concentration was adjusted to 5X 10 6 cells/mL。
Centrifuging lactobacillus activated bacteria liquid at 4000rpm at room temperature for 10min to remove supernatant, washing twice with PBS, adding appropriate amount of RPMI-1640 medium containing 10% foetal calf serum, and adjusting OD 600 To 0.50 + -0.10. Cell suspensions were added to 96-well cell culture plates, 3 replicates per sample. A zeroing group (cell culture medium), a blank group (cell suspension+cell culture medium, inducer group (cell suspension+10. Mu.g/mL Con A), a lactic acid bacteria group (cell suspension+10. Mu.g/mL Con A+bacterial suspension) were set, and incubated at 37℃for 72 hours in a carbon dioxide incubator, 20. Mu.L of MTT solution (2.5 mg/mL) was added to each well, after development at 37℃for 4 hours, centrifugation was performed at 1500rpm at 4℃for 10 minutes, the supernatant was aspirated, and 100. Mu.L of DMSO was added thereto, and absorbance was measured at 490nm using an microplate reader.
Data analysis: probiotics which significantly promote spleen lymphocyte proliferation, both with and without induction by Con a, were used as preferred strains.
The results are shown in the following table, where the multiplication factor of lactobacillus helveticus WHH2580 spleen lymphocytes was higher than that of the two commercial strains, with and without induction by Con a.
2 in vitro spleen lymphocyte cytokine IL-10 and IL-12 assays
Cell sampling, erythrocyte lysis, washing, cell counting and probiotics culture are the same as the in vitro spleen lymphocyte proliferation step. The cell suspension was added to 96-well cell culture plates, each treatment was repeated 5 times, and the treatment was divided into zeroing groups (100. Mu.L of cell culture medium), blank groups (1X 10) 7 cell suspension 100. Mu.l, cell culture medium 100. Mu.l, cell/mL, probiotic group (1X 10) 7 cell suspension 100. Mu.L, 1X 10 in cells/mL 8 cfu/mL of bacterial suspension 100. Mu.L), 5% CO at 37 ℃ 2 Culturing in an incubator for 24 hours. 1500 Centrifugation at rpm for 10min, the supernatant was aspirated, filtered through a 0.22 μm filter, and the IL-10 and IL-12 content was determined using BD kit.
Strains with a high IL-12/IL-10 ratio can be used as immunoregulatory potential strains.
The results are shown in the following table, where the ratio of Lactobacillus helveticus WH2580 IL-12/IL-10 is close to that of Lactobacillus rhamnosus LGG, and is not significantly inferior.
3 in vitro determination of human colon cancer cell HT-29 cytokine IL-8
Digesting human colon cancer cells HT-29 which grow and fuse to 70% -80%, and regulating cell concentration to 1 x 10 6 The cells/holes are connected into 24-hole plates for culture at 37 ℃ and liquid exchange is carried out after 24 hours. Treated with 20ng/mL LPS for 6 hours and then added with 8X 10 8 After 18 hours of treatment of CFU/mL bacterial liquid, 3000r/min and 5min are centrifuged to obtain supernatant, and the content of interleukin IL-8 is detected by using a corresponding ELISA kit.
The strain secreting high IL-8 can be used as an immunoregulatory potential strain.
The results are shown in the following table.
Strain numbering | IL-8 concentration (ng/mL) |
Lactobacillus rhamnosus LGG | 2981±95 |
Lactobacillus helveticus WHH2580 | 4021±145 |
Lactobacillus helveticus WH2580 IL-8 is higher than the commercial strain LGG.
Example 15: animal test
Inbred BALB/C male mice (6-8 weeks old, 16-20 g) were randomly grouped into 8 groups of 12 mice each with a 5 day adaptation period, using a random grouping design. The animal feeding keeps the ambient temperature at 21+/-2 ℃ and the humidity at 30-70%, the illumination is alternated for 12 hours, the animals can drink water and take feed freely. The padding is changed every three days, and water and feed are added in time. The grouping is as follows:
control group 1: blank control group, lavage water;
control group 2: model control group, lavage water + intraperitoneal injection of 50mg/kg cyclophosphamide for molding;
Control group 3: positive medicine group, lavage 40mg/kg levamisole hydrochloride + intraperitoneal injection 50mg/kg cyclophosphamide mould;
experiment group 1: the strain bacterial suspension of the invention is used for stomach irrigation, and the stomach irrigation dosage is 2-10 8 CFU/d;
Experiment group 2: the strain inactivated bacterial suspension is used for lavage, and the dosage for lavage is 2 x 10 8 CFU/d;
Wherein the inactivated bacteria are treated at 80deg.C for 10 min. The presence of the viable bacteria was confirmed by plate culture.
The test was performed using immunocompromised model animals. The subjects were administered continuously for 38 days, and administration of immunosuppressant was started after day 32. The body weight was weighed once a week before the inhibitor, and once a day after the inhibitor. The detection is started on the 5 th day of intraperitoneal injection of immunosuppressant, and the detection indexes include organ ratio, spleen lymphocyte proliferation and NK cell activity.
The experimental results are as follows:
the body weight results are shown in FIG. 9. The trend of body weight change was similar for each experimental group except for the blank, and body weight was reduced on the first day after injection of the inhibitor, followed by gradual recovery.
The organ ratio results are shown in FIG. 10. The thymus/body weight ratio and spleen/body weight ratio were significantly lower in the model group than in the control group. The thymus/body weight ratio was significantly higher in the low dose and positive drug groups than in the model group (P < 0.05), and in the high dose and dead bacteria groups than in the model group (P < 0.001). The spleen/body weight ratio was significantly higher in the low, medium, dead and positive drug groups than in the model group (P < 0.05).
The proliferation results of the spleen lymphocytes of the mice are shown in FIG. 11. The OD value of the ultra-low dose group, the medium dose group and the high dose group is obviously higher than that of the inactivated bacteria group of the model group and is obviously higher than that of the model group. The WHH2580 ultra-low dose, low, medium, high dose and inactivated bacteria can obviously promote the proliferation of spleen lymphocytes of immunocompromised mice.
The results of the determination of NK cell activity in mice are shown in FIG. 12. The NK cell activity of the medium-dose group is remarkably higher than that of the model group, and the NK cell activity of the inactivated bacteria group is remarkably higher than that of the model group. The results show that the NK cell activity of the immunocompromised mice can be obviously improved by the dosage and the inactivated bacteria in WH 2580.
According to the health product function evaluation method, under the condition that an immune function hypofunction model is established, the total number of blood leucocytes, the cellular immune function (a mouse spleen lymphocyte transformation experiment, a delayed type allergy experiment), the humoral immune function (an antibody generation cell detection, a serum hemolysin measurement), the mononuclear-macrophage function (a mouse carbon clearance experiment, a mouse peritoneal macrophage phagocytosis fluorescent microsphere experiment) and NK cell activity are positive, and the tested sample is judged to have the effect of enhancing the immunity of a person with the immune hypofunction. The WH 2580 strain has positive test results on the aspects of cellular immune function and NK cell activity, and can be judged that the WH 2580 strain has the effect of enhancing the immunity of immunocompromised persons.
The WH 2580 inactivated strain can also improve the immunity of the organism by improving and regulating the organ index, nonspecific immunity and specific immune response of the organism.
The raw materials and equipment used in the invention are common raw materials and equipment in the field unless specified otherwise; the methods used in the present invention are conventional in the art unless otherwise specified.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and any simple modification, variation and equivalent transformation of the above embodiment according to the technical substance of the present invention still fall within the scope of the technical solution of the present invention.
Sequence listing
<110> Hangzhou child haha technology Co., ltd
Hangzhou Wahaha Group Co.,Ltd.
<120> sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1425
<212> DNA
<213> Lactobacillus helveticus (Lactobacillus helveticus)
<400> 1
ccttcccgaa ggttaggcca ccggctttgg gcattgcaga cttccatggt gtgacgggcg 60
gtgtgtacaa ggcccgggaa cgtattcacc gcggcgttct gatccgcgat tactagcgat 120
tccagcttcg tgcagtcgag ttgcagactg cagtccgaac tgagaacagc tttcagagat 180
tcgcttgcct tcgcaggctc gcttctcgtt gtactgtcca ttgtagcacg tgtgtagccc 240
aggtcataag gggcatgatg acttgacgtc atccccacct tcctccggtt tatcaccggc 300
agtctcatta gagtgcccaa cttaatgctg gcaactaata acaagggttg cgctcgttgc 360
gggacttaac ccaacatctc acgacacgag ctgacgacag ccatgcacca cctgtcttag 420
cgtccccgaa gggaactcct aatctcttag gatggcacta gatgtcaaga cctggtaagg 480
ttcttcgcgt tgcttcgaat taaaccacat gctccaccgc ttgtgcgggc ccccgtcaat 540
tcctttgagt ttcaaccttg cggtcgtact ccccaggcgg agtgcttaat gcgttagctg 600
cagcactgag aggcggaaac ctcccaacac ttagcactca tcgtttacgg catggactac 660
cagggtatct aatcctgttc gctacccatg ctttcgagcc tcagcgtcag ttgcagacca 720
gagagtcgcc ttcgccactg gtgttcttcc atatatctac gcattccacc gctacacatg 780
gagttccact ctcctcttct gcactcaaga aaaacagttt ccgatgcagt tcctcggtta 840
agccgagggc tttcacatca gacttattct tccgcctgcg ctcgctttac gcccaataaa 900
tccggacaac gcttgccacc tacgtattac cgcggctgct ggcacgtagt tagccgtgac 960
tttctggttg attaccgtca aataaaggcc agttactacc tctatccttc ttcaccaaca 1020
acagagcttt acgatccgaa aaccttcttc actcacgcgg cgttgctcca tcagacttgc 1080
gtccattgtg gaagattccc tactgctgcc tcccgtagga gtttgggccg tgtctcagtc 1140
ccaatgtggc cgatcagtct ctcaactcgg ctatgcatca ttgccttggt aagccgttac 1200
cttaccaact agctaatgca ccgcggggcc atcccatagc gacagcttac gccgcctttt 1260
ataagctgat catgcgatct gctttcttat ccggtattag cacctgtttc caagtggtat 1320
cccagactat ggggcaggtt ccccacgtgt tactcaccca tccgccgctc gcgtccccag 1380
cgtcattacc gaagtaaatc tgctggttct gctcgctcga cttgc 1425
Claims (10)
1. The sucrose-free yoghurt with the normal temperature and long shelf life for improving the immunity is characterized by comprising raw milk or milk powder and an immunity-improving functional component; the immunity improving functional ingredient at least comprises lactobacillus helveticus;
the lactobacillus helveticus is named WHH2580, and the microorganism deposit number is: CGMCC No.18730, the microorganism classification is named as Lactobacillus helveticus Lactobacillus helveticusThe method comprises the steps of carrying out a first treatment on the surface of the The lactobacillus helveticus has a 16s rRNA gene sequence shown as SEQ ID NO. 1.
2. The sucrose-free yogurt of claim 1, further comprising sugar alcohols, starches, stabilizers, sweeteners.
3. The sucrose-free yogurt with the normal temperature and long shelf life for improving immunity according to claim 2, wherein the yogurt comprises, by mass, 40% -85% of raw milk or 5% -15% of milk powder, 0.001% -0.020% of lactobacillus helveticus, 0.01% -10.00% of immunity-improving efficacy components except lactobacillus helveticus, 0.5% -5.0% of sugar alcohol, 0.1% -5.0% of starch, 0.01% -1.00% of stabilizer, 0.001% -0.050% of sweetener and the balance of water; the sum of all the raw materials is 100%.
4. A sucrose-free yogurt of claim 2 or 3 having a long shelf life at ambient temperature for enhancing immunity, characterized in that:
the milk powder is one or more of full-fat milk powder, defatted milk powder, whey protein powder and full-milk protein powder; and/or
The immunity improving functional ingredient also comprises one or more of propolis, ganoderma lucidum extract, wall-broken ganoderma lucidum spore powder, beta-glucan, dendrobium candidum extract, elderberry and acerola cherry; and/or
The sugar alcohol is one or more of xylitol, maltitol, erythritol, sorbitol, isomaltulose alcohol and lactitol; and/or
The starch is one or more of physical starch, acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate and acetylated distarch adipate; and/or
The stabilizer is one or more of sodium carboxymethyl cellulose, pectin, soybean polysaccharide, agar, sodium caseinate, propylene glycol alginate, gelatin, gellan gum, guar gum and xanthan gum; and/or
The sweetener is one or more of acesulfame potassium, aspartame, sucralose, stevioside, mogroside, isomaltulose, alitame and neotame.
5. A method for preparing the sucrose-free yogurt with enhanced immunity and long shelf life at normal temperature according to any one of claims 2 to 4, comprising the steps of:
scheme a:
(1) Homogenizing and sterilizing: preheating raw milk, homogenizing, sterilizing, and cooling to obtain sterilizing and cooling feed liquid;
(2) Inoculating and fermenting: adding lactobacillus helveticus into the sterilization cooling feed liquid obtained in the step (1), stirring and mixing uniformly, standing and fermenting at constant temperature to obtain a yoghurt base material;
(3) Preparing glue solution: preheating water, adding stabilizer in the amount of formula into water, shearing or stirring, and cooling to obtain glue solution;
(4) And (3) secondary batching: cooling the yoghurt base material obtained in the step (2), and then stirring and demulsifying; adding the glue solution obtained in the step (3), adding the immunity improving functional components except lactobacillus helveticus, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and fixing the volume by water to obtain a feed liquid;
(5) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step (4);
(6) Filling and sterilizing: filling, sealing, pasteurizing and cooling the homogenized feed liquid in the step (5) to obtain the normal-temperature long-shelf-life sucrose-free yoghourt capable of improving the immunity; or sterilizing the homogenized feed liquid in the step (5) by UHT, hot filling or sterile cold filling, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yoghurt with improved immunity;
scheme B:
1) Preparing milk: heating water, adding milk powder with the formula amount into the water, stirring or shearing, standing and hydrating to obtain milk;
2) Homogenizing and sterilizing: preheating the milk obtained in the step 1), homogenizing, sterilizing and cooling to obtain sterilizing and cooling feed liquid;
3) Inoculating and fermenting: adding lactobacillus helveticus into the sterilization cooling feed liquid obtained in the step 2), stirring and mixing uniformly, and standing and fermenting at constant temperature to obtain a yoghurt base material;
4) Preparing glue solution: preheating water, adding stabilizer in the amount of formula into water, shearing or stirring, and cooling to obtain glue solution;
5) And (3) secondary batching: cooling the yoghurt base material obtained in the step 3), and then stirring and demulsifying; adding the glue solution obtained in the step 4), adding the immunity improving functional components except lactobacillus helveticus, sugar alcohol, sweetener and starch in the formula dosage, mixing and stirring, and fixing the volume by water to obtain a feed liquid;
6) And (3) secondary homogenization: homogenizing the feed liquid obtained in the step 5);
7) Filling and sterilizing: filling, sealing, pasteurizing and cooling the homogenized feed liquid in the step 6) to obtain the normal-temperature sucrose-free yogurt with long shelf life and improved immunity; or sterilizing the homogenized feed liquid in the step 6) by UHT, hot filling or sterile cold filling, and sealing to obtain the normal-temperature long-shelf-life sucrose-free yogurt with improved immunity.
6. The method for preparing the sucrose-free yogurt with the immunity-enhancing normal temperature and long shelf life of claim 5, wherein the method comprises the following steps:
in the step 1), the mass of the water is 200-400g; and/or
In the step 1), water is heated to 45-60 ℃; and/or
In the step 1), stirring or shearing time is 15-30min; and/or
In the step 1), standing and hydrating time is 20-40min.
7. The method for preparing the sucrose-free yogurt with the immunity-enhancing normal temperature and long shelf life of claim 5, wherein the method comprises the following steps:
in the step (1) or the step (2), preheating to 60-65 ℃; and/or
In the step (1) or the step (2), the homogenizing pressure is 0-8/5-30MPa; and/or
In the step (1) or the step (2), the sterilization temperature is 90-97 ℃ and the sterilization time is 3-10min; and/or
In step (1) or step 2), cooling to a temperature of 35-45 ℃.
8. The method for preparing the sucrose-free yogurt with the immunity-enhancing normal temperature and long shelf life of claim 5, wherein the method comprises the following steps:
in the step (2) or the step (3), the fermentation temperature is 35-45 ℃ and the fermentation time is 4-16h; and/or
In the step (2) or the step (3), the number of viable bacteria is more than or equal to 1 multiplied by 10 in the fermentation process 8 cfu/mL。
9. The method for preparing the sucrose-free yogurt with the immunity-enhancing normal temperature and long shelf life of claim 5, wherein the method comprises the following steps:
In the step (3) or the step 4), the mass of the water is 200-400g; and/or
In the step (3) or the step 4), water is preheated to 50-60 ℃; and/or
In the step (3) or the step (4), the shearing or stirring time is 20-40min; and/or
In the step (3) or the step (4), the temperature is cooled to below 30 ℃.
10. The method for preparing the sucrose-free yogurt with the immunity-enhancing normal temperature and long shelf life of claim 5, wherein the method comprises the following steps:
in the step (4) or the step (5), cooling to a temperature below 15 ℃; and/or
In the step (4) or the step (5), water is used for fixing the volume to 1000mL; and/or
In the step (5) or the step (6), the homogenizing pressure is 0-8/5-30MPa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010518902.XA CN111728030B (en) | 2020-06-09 | 2020-06-09 | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010518902.XA CN111728030B (en) | 2020-06-09 | 2020-06-09 | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111728030A CN111728030A (en) | 2020-10-02 |
CN111728030B true CN111728030B (en) | 2023-04-28 |
Family
ID=72650033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010518902.XA Active CN111728030B (en) | 2020-06-09 | 2020-06-09 | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111728030B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114680337B (en) * | 2022-03-21 | 2024-01-30 | 杭州娃哈哈科技有限公司 | Application of lactobacillus helveticus in preparation of antihypertensive fermentation product |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109022323A (en) * | 2018-08-24 | 2018-12-18 | 诺佰克(武汉)生物科技有限公司 | A kind of Lactobacillus helveticus complexing agent and its preparation method and application |
CN109820044A (en) * | 2018-07-13 | 2019-05-31 | 拜尔普兰(厦门)生物药业有限公司 | A kind of strengthen immunity and assist antianaphylactic probiotics solid beverage formula |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102388962B (en) * | 2011-11-08 | 2013-05-01 | 杭州娃哈哈科技有限公司 | Normal-temperature yoghourt and preparation method thereof |
CN102453689B (en) * | 2011-12-06 | 2014-04-09 | 光明乳业股份有限公司 | Lactobacillus plantarum strain producing extracellular polysaccharide, and application thereof |
CN102845518A (en) * | 2012-10-17 | 2013-01-02 | 石家庄君乐宝乳业有限公司 | Yoghourt with health-care function, as well as preparation method and application thereof |
CN106376644A (en) * | 2016-08-29 | 2017-02-08 | 杭州娃哈哈科技有限公司 | Long shelf-life and refrigerated live bacterium yogurt and preparation method thereof |
-
2020
- 2020-06-09 CN CN202010518902.XA patent/CN111728030B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109820044A (en) * | 2018-07-13 | 2019-05-31 | 拜尔普兰(厦门)生物药业有限公司 | A kind of strengthen immunity and assist antianaphylactic probiotics solid beverage formula |
CN109022323A (en) * | 2018-08-24 | 2018-12-18 | 诺佰克(武汉)生物科技有限公司 | A kind of Lactobacillus helveticus complexing agent and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN111728030A (en) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114032193B (en) | Lactobacillus paracasei 207-27 and application thereof | |
US7390519B2 (en) | Probiotic Lactobacillus salivarius strains | |
CN100552016C (en) | The bifidus bacillus that is used for the treatment of inflammatory diseases | |
US8557233B2 (en) | Probiotic bifidobacterium strains | |
CN101679938B (en) | Probiotic bifidobacterium strains | |
US20030092163A1 (en) | Probiotic bifidobacterium strains | |
CN111484957A (en) | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof | |
CN111944727B (en) | Bifidobacterium breve 207-1 and application thereof | |
CN110964657B (en) | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof | |
KR101452234B1 (en) | Novel Lactobacillus fermentum isolated from healthy adults in the Korean longevity villages which promote regular bowel movement | |
US20030113306A1 (en) | Probiotic lactobacillus casei strains | |
CN114480229B (en) | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof | |
EP2522358A1 (en) | Peptides against rotavirus infection | |
JP2020074751A (en) | Bifidobacterium lactis gkk2, composition containing the same, and uses thereof for amelioration of allergic asthma | |
CN111543640A (en) | Application of bifidobacterium animalis subsp lactis i797 for improving infantile diarrhea and dyspepsia | |
CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
CN111728030B (en) | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof | |
CN111254087B (en) | Lactobacillus helveticus with high adhesion performance and function of enhancing immunity and application thereof | |
CN111743158B (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
KR102146706B1 (en) | Composition for improving allergic rhinitis containing fermented red ginseng concentrate having increased content of ginsenoside Rd using fermentation by Bifidobacterium animalis ssp. lactis HY8002 and Bifidobacterium adolescentis HY8502 mixture as effective component | |
RU2491336C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in individuals of fourteen and older, and method for preparing it, dietary supplement for correcting gastrointestinal microflora in individuals of fourteen and older and bacterial preparation for treating dysbiotic gastrointestinal conditions in individuals of fourteen and older | |
CN113462616A (en) | Humanized lactobacillus rhamnosus GLR8 and preparation method thereof | |
Soyer et al. | Determination of potential probiotic properties of lactic acid bacteria isolated from colostrum milk | |
RU2491331C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in children under age of three, and method for preparing it, dietary supplement and bacterial preparation for treating dysbiotic gastrointestinal conditions in children under age of three | |
RU2151797C1 (en) | Strain lactobacillus acidophilus k/ar-0,8 is resistant to antibiotics and salt-resistant antagonist pathogens of intestine infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |